Patent ID: 7056502

Claim:
A method of delivering a heterologous molecule to a selected mammalian or veterinary patient, comprising: contacting the cells of the patient with a recombinant type 5 adeno-associated virus (rAAV5), said rAAV5 comprising: a minigene comprising AAV 5′ ITRs, a heterologous nucleic acid molecule, wherein said nucleic acid molecule is a transgene comprising a nucleic acid sequence encoding a product which is under the control of regulatory sequences which direct expression of the product in a host cell, and AAV 3′ ITRs; an AAV5 capsid in which said transgene is packaged; wherein said minigene comprises AAV ITR sequences from a serotype heterologous to AAV5, and contacting the cells of the patient with a second rAAV, wherein the second rAAV comprising AAV 5′ ITRs, a transgene comprising a nucleic acid sequence encoding a product which is under the control of regulatory sequences which direct expression of the product in a host cell, and AAV 3′ ITRs, packaged in an AAV capsid which is from a serotype different from that of the rAAV5 capsid.